MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart ...
-- Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy -- Reprieve ...
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results ...
Reprieve Cardiovascular recently emerged from stealth mode after raising $42 million in series A financing. The Milford, MA-based company is developing a system intended to personalize decongestion ...
During the conference, Mr. Pacyna will discuss Reprieve’s recent corporate and clinical milestones, including the ongoing enrollment in the Company’s pivotal FASTR II clinical trial. The presentation ...
Hosted on MSN
Reprieve secures $61m for ADHF system trial
Reprieve Cardiovascular has closed an oversubscribed $61m Series B financing round, which was spearheaded by Deerfield Management. The funds aim to accelerate the global FASTR II pivotal trial of the ...
German-American medical device firm, Reprieve Cardiovascular, is eyeing up a pivotal trial with its cardiovascular drainage device after reporting success from a first-in-human study. Results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results